Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 2
1960 1
1973 1
1974 3
1975 2
1976 1
1982 1
1991 1
1994 1
1995 1
1996 2
1997 3
1998 1
1999 2
2000 2
2001 1
2003 2
2004 1
2005 1
2006 2
2007 1
2010 2
2011 3
2012 6
2013 4
2014 3
2015 8
2016 12
2017 20
2018 16
2019 19
2020 31
2021 25
2022 21
2023 17
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, Tadros J, Ferretti AP, Liao S, Gurer C, Chen YH, Criscitiello S, Ricker CA, Dionne D, Rozenblatt-Rosen O, Uppaluri R, Haddad RI, Ashenberg O, Regev A, Van Allen EM, MacBeath G, Schoenfeld JD, Wucherpfennig KW. Luoma AM, et al. Among authors: schoenfeld jd. Cell. 2022 Aug 4;185(16):2918-2935.e29. doi: 10.1016/j.cell.2022.06.018. Epub 2022 Jul 7. Cell. 2022. PMID: 35803260 Free PMC article.
Using immunotherapy to boost the abscopal effect.
Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Ngwa W, et al. Among authors: schoenfeld jd. Nat Rev Cancer. 2018 May;18(5):313-322. doi: 10.1038/nrc.2018.6. Epub 2018 Feb 16. Nat Rev Cancer. 2018. PMID: 29449659 Free PMC article. Review.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Among authors: schoenfeld jd. Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665297 Free PMC article. Clinical Trial.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira G, Egloff AM, Afeyan AB, Wolff JO, Zeng Z, Chernock RD, Zhou L, Messier C, Lizotte P, Pfaff KL, Stromhaug K, Penter L, Haddad RI, Hanna GJ, Schoenfeld JD, Goguen LA, Annino DJ, Jo V, Oppelt P, Pipkorn P, Jackson R, Puram SV, Paniello RC, Rich JT, Webb J, Zevallos JP, Mansour M, Fu J, Dunn GP, Rodig SJ, Ley J, Morris LGT, Dunn L, Paweletz CP, Kallogjeri D, Piccirillo JF, Adkins DR, Wu CJ, Uppaluri R. Oliveira G, et al. Among authors: schoenfeld jd. Sci Immunol. 2023 Sep 8;8(87):eadf4968. doi: 10.1126/sciimmunol.adf4968. Epub 2023 Sep 8. Sci Immunol. 2023. PMID: 37683037 Free PMC article.
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI. Schoenfeld JD, et al. JAMA Oncol. 2020 Oct 1;6(10):1563-1570. doi: 10.1001/jamaoncol.2020.2955. JAMA Oncol. 2020. PMID: 32852531 Free PMC article. Clinical Trial.
Radiation Therapy and Immune Modulation.
Leeman JE, Schoenfeld JD. Leeman JE, et al. Among authors: schoenfeld jd. Hematol Oncol Clin North Am. 2019 Apr;33(2):233-248. doi: 10.1016/j.hoc.2018.12.003. Epub 2019 Jan 17. Hematol Oncol Clin North Am. 2019. PMID: 30832997 Review.
Immunotherapy and radiotherapy for metastatic cancers.
Bang A, Schoenfeld JD. Bang A, et al. Among authors: schoenfeld jd. Ann Palliat Med. 2019 Jul;8(3):312-325. doi: 10.21037/apm.2018.07.10. Epub 2018 Aug 22. Ann Palliat Med. 2019. PMID: 30180743 Free article. Review.
202 results